Amphetamine Use
Find comprehensive information on Amphetamine Use, including Amphetamine Abuse and Amphetamine Dependence, for healthcare professionals. This resource covers clinical documentation, medical coding, and Stimulant Use Disorder diagnosis. Learn about accurate diagnostic criteria, treatment options, and best practices for documenting amphetamine-related conditions in medical records. Improve your understanding of amphetamine use disorders and related healthcare terminology.
Stimulant use causing significant impairment or distress.
Increased heart rate, elevated mood, agitation, paranoia, weight loss.
Outpatient clinics, addiction treatment centers, emergency rooms.
ICD-10 Code Families
Complete code families applicable to F15.90
When to use each related code
| Description | When to use |
|---|---|
| Stimulant use causing impairment. | Primary diagnosis for harmful amphetamine use. Consider severity and related conditions. |
| Stimulant-induced psychosis. | If psychotic symptoms are present due to amphetamine use, use in addition to Amphetamine Use diagnosis. |
| Stimulant withdrawal. | For symptoms following cessation of amphetamine use after prolonged or heavy use. |
Best-practice checklist
- ✓Amphetamine use ICD-10 F15.90, DSM-5 304.40: Document frequency, amount, route.
- ✓Stimulant use disorder: Note onset, duration, impact on daily life.
- ✓Amphetamine abuse/dependence: Assess withdrawal symptoms, cravings.
- ✓Document related social/occupational impairment (e.g., job loss).
- ✓Include any co-occurring mental health disorders (dual diagnosis).
Common pitfalls to avoid
Coding requires specifying the type of amphetamine (e.g., methamphetamine, dextroamphetamine) for accurate reimbursement and data analysis. Missing specificity can lead to claim denials and skewed data.
Incorrectly coding amphetamine use as dependence or vice versa can impact severity scores and reimbursement. Clear documentation differentiating use, abuse, and dependence is crucial.
Amphetamine use often co-occurs with mental health disorders. Failing to capture and code these comorbidities can lead to inaccurate risk adjustment and underpayment.
Best-practice tips
- 01Document amphetamine type, frequency, and route of administration.
- 02Screen for co-occurring mental health disorders (ICD-10 F15).
- 03Assess cardiovascular risks and document vital signs consistently.
- 04Develop a patient-centered treatment plan including therapy (CPT 90837).
- 05Monitor medication adherence for prescribed amphetamine alternatives.
Step-by-step checklist
- 1
Verify patient history of amphetamine use (ICD-10 F15.10, DSM-5 304.40).
- 2
Document amphetamine-related symptoms (e.g., tachycardia, agitation).
- 3
Screen for other substance use disorders and mental health conditions.
- 4
Consider urine drug screen to confirm amphetamine presence.
Ready-to-paste narrative
Patient presents with symptoms suggestive of Amphetamine Use Disorder, also documented as Amphetamine Abuse, Amphetamine Dependence, or Stimulant Use Disorder. Clinical indicators include reported euphoria followed by crashes, increased energy, rapid speech, dilated pupils, and significant weight loss. Patient acknowledges a pattern of amphetamine use, escalating doses, and unsuccessful attempts to quit, meeting DSM-5 criteria for stimulant use disorder. The patient exhibits cravings, withdrawal symptoms such as fatigue and depression, and neglect of social obligations due to drug seeking behavior. Differential diagnosis considered other stimulant-induced disorders and primary mood disorders. Assessment includes a comprehensive substance use history, mental status examination, and laboratory testing to evaluate for amphetamine toxicity and co-occurring medical conditions. Treatment plan includes referral to addiction medicine specialist for medication-assisted treatment options such as bupropion or naltrexone, individual therapy focusing on cognitive behavioral therapy (CBT) techniques for relapse prevention, and support groups. Patient education provided on the risks of amphetamine use, including cardiovascular complications, neurological damage, and overdose potential. Prognosis depends on patient engagement in treatment and adherence to the recovery plan. Follow-up scheduled to monitor progress, adjust treatment as needed, and address any withdrawal symptoms or cravings. ICD-10 code F15.10 assigned for Amphetamine Use, unspecified. CPT codes will be determined based on the specific therapeutic interventions provided.
Common questions and answers
What are the most effective evidence-based treatment approaches for adult patients with amphetamine use disorder, considering both pharmacological and psychosocial interventions?+
Effective treatment for amphetamine use disorder typically involves a combination of pharmacological and psychosocial interventions. Psychosocial approaches like contingency management (CM), cognitive behavioral therapy (CBT), and motivational interviewing (MI) have demonstrated efficacy in improving treatment retention and reducing amphetamine use. While no FDA-approved medications specifically target amphetamine use disorder, medications like bupropion and naltrexone may be considered for managing co-occurring conditions or reducing cravings, though further research is needed to establish their definitive role in amphetamine dependence treatment. Consider implementing a comprehensive treatment plan that integrates evidence-based psychosocial interventions like CBT and CM and explores potential off-label medication options based on individual patient needs and comorbidities. Explore how integrating motivational enhancement therapy (MET) can improve patient engagement in treatment. Learn more about the latest research on promising pharmacological treatments for stimulant use disorder.
How can clinicians accurately differentiate between amphetamine intoxication, amphetamine withdrawal, and other stimulant-induced psychiatric disorders during a diagnostic assessment?+
Differentiating between amphetamine intoxication, withdrawal, and other stimulant-induced psychiatric disorders requires careful consideration of the patient's symptom presentation, timeline of substance use, and past psychiatric history. Amphetamine intoxication often presents with tachycardia, hypertension, dilated pupils, agitation, and psychosis. Withdrawal, conversely, is characterized by dysphoria, fatigue, increased appetite, vivid dreams, and psychomotor retardation. Stimulant-induced disorders, such as stimulant-induced psychotic disorder or stimulant-induced anxiety disorder, can mimic primary psychiatric conditions but are temporally related to amphetamine use. Accurate diagnosis involves thorough clinical evaluation, including a detailed substance use history, mental status examination, and potentially laboratory testing to rule out other medical or psychiatric conditions. Consider implementing standardized assessment tools like the DSM-5 criteria and exploring the role of toxicology screening in aiding differential diagnosis. Learn more about the specific diagnostic criteria for amphetamine-related and other stimulant-induced disorders to ensure accurate assessment and appropriate treatment planning.
What specific strategies can clinicians employ to address treatment resistance and high relapse rates in patients with long-term amphetamine dependence and co-occurring mental health disorders?+
Addressing treatment resistance and high relapse rates in patients with long-term amphetamine dependence and co-occurring mental health disorders requires a multi-faceted approach. Integrated treatment models that address both substance use and mental health conditions concurrently are crucial. Strategies like motivational interviewing can help enhance patient motivation and engagement in treatment, while relapse prevention planning equips patients with coping skills to manage triggers and high-risk situations. Consider implementing contingency management strategies to reinforce abstinence and exploring the potential benefits of peer support groups or recovery coaching. For patients with co-occurring disorders, optimizing medication management for both conditions is essential. Learn more about the principles of harm reduction and how they can be incorporated into treatment for amphetamine dependence to minimize the negative consequences associated with continued use.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.